Exchange: NASDAQ·Updated 05:35 AM EDT
DBVT logo

DBVT DBV Technologies

$8.71
$0.34
(3.76%)
Pre-Market
Prev Close $9.05
EarningsOct 28
Mkt Cap$568.78M
Vol430.00

About DBVT

DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The firm focuses on the development of Viaskin, an electrostatic patch, which may offer a convenient, self-administered, and non-invasive immunotherapy to patients. It also designs a robust clinical development program that includes ongoing clinical trials of Viaskin peanut, and Viaskin milk, as well as pre-clinical development of Viaskin egg. The company was founded by Pierre-Henri Benhamou, Stéphane Benhamou, Bertrand Dupont, Christophe Dupont, and Pierre-Yves Vannerom on March 29, 2002 and is headquartered in Chatillon, France.
60

Bullish Sentiment

How do you feel about DBVT?

Advertisement|Remove ads.